Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting

BACKGROUND: In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still unclear and no second-line agent has proven its efficacy. OBJECTIVES: The aim of this retrospective multicenter real-world cohort study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Falette-Puisieux, Manon, Nault, Jean-Charles, Bouattour, Mohamed, Lequoy, Marie, Amaddeo, Giuliana, Decaens, Thomas, Di Fiore, Frederic, Manfredi, Sylvain, Merle, Philippe, Baron, Aurore, Locher, Christophe, Pellat, Anna, Coriat, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399252/
https://www.ncbi.nlm.nih.gov/pubmed/37547443
http://dx.doi.org/10.1177/17588359231189425

Ejemplares similares

Ejemplares similares